FDA Moves Forward on Influenza Prevention and Pandemic Management

A Food and Drug Administration (FDA) advisory panel unanimously agreed to approve FluMist, the nasal influenza vaccine, for use in children under five years old. The advisory panel raised concerns, however, about the use of the vaccine in children younger than two. A significant minority would not give approval to administer the nasal vaccine to…